Business Wire

Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting

Del

Immunocore, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune disease, today announced that positive data from the first in human, Phase I clinical trial of its lead ImmTAC (Immune mobilising monoclonal TCRs Against Cancer), IMCgp100, was presented in a poster discussion session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 5th 2016.

IMCgp100 is a first-in-class bi-specific biologic known as a T cell redirector. This ImmTAC binds, with picomolar affinity, to a melanoma associated target, gp100; once bound IMCgp100 redirects all T cells, including non-cancer specific T cells, to kill the cancer cells.

In a presentation entitled: “Safety, Pharmacokinetics and Efficacy of IMCgp100, a First-in-Class Soluble TCR Anti-CD3 Bispecific T Cell Redirector With Solid Tumour Activity: Results From the FIH Study in Melanoma” Mark Middleton MD, Professor of Experimental Cancer Medicine at the University of Oxford, and Principal Investigator for the Study, presented data from the First-In-Human study of IMCgp100 in metastatic melanoma, treating 84 patients in total.

In the study, IMCgp100 showed a favourable safety profile at the established recommended Phase II dose, with prolonged responses observed in both uveal and cutaneous melanoma. Tumour shrinkages in patients with a particularly poor prognosis and those with checkpoint resistant disease were also reported. Some immune mediated toxicities were observed predominantly in the first few doses and were manageable. Rapid T cell infiltration into tumours coinciding with immune activation occurred within days following the first dose in both cutaneous and uveal melanoma patients.

Mark Middleton, Principal Investigator, commented: “These are promising data, we know how to give the drug safely and we are seeing prolonged responses in both uveal and cutaneous melanoma. It is also really encouraging to see tumours shrink in patients with high LDH and/or liver tumour burden. These exciting data strongly support the further development of IMCgp100, in patients with uveal and cutaneous melanoma.”

Dr. Christina Coughlin, Chief Medical Officer of Immunocore, added: “We are delighted that the data strongly supports the expansion of the IMCgp100 programme into both cutaneous and uveal melanoma Phase II trials and we look forward to progressing our lead programme through further clinical development.”

In January 2016 the US Food and Drug Administration (FDA) also granted Orphan Drug Designation to IMCgp100 for the treatment of uveal melanoma. Furthermore, Immunocore has participated in the European Medicines Agency’s (EMA) Adaptive Pathway pilot programme with IMCgp100. Earlier this year, Immunocore initiated a Phase I clinical study of IMCgp100 in patients with uveal melanoma and a combination Phase Ib/II trial with MedImmune’s checkpoint inhibitors durvalumab and tremelimumab.

- ENDS –

Notes for editors

About Immunocore

Immunocore is one of the world’s leading biotechnology companies, with a highly innovative immuno-oncology platform technology called ImmTACs. ImmTACs are a novel class of biologic drugs based on the Company’s proprietary T cell receptor (TCR) technology which have the potential to treat diseases with high unmet medical need including cancer, infectious diseases and autoimmune diseases. Immunocore, based on decades of world-leading scientific innovation in the discovery of HLA targets and T cell receptor technology, has a pipeline of wholly-owned and partnered ImmTAC programmes with robust clinical data, validated by collaborations with world-leading pharmaceutical companies. Immunocore is developing programmes with its TCR-based platform as a potential therapy for HIV and other infectious diseases, ImmTAVs. Immunocore aims to leverage the utility of its platform across a wide range of indications to become a Premier Biotech company and world-leader in its field.

Immunocore’s world-leading science and strong IP position has attracted major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, via discovery collaborations, as well as a co-discovery and co-development partnership with Lilly. The Company has also entered into combination trials with its lead programme, IMCgp100 in melanoma, with MedImmune and Lilly. Founded in 2008 originally out of Oxford University and headquartered outside Oxford with US offices outside Philadelphia, Immunocore has more than 220 staff. Immunocore’s current investors are well-renowned, leading international institutions including Woodford Investment Management, Malin Corporation, Eli Lilly and Company, RTW Investments, Fidelity Management & Research Company as well as other private shareholders. For more information, please visit www.immunocore.com

About ImmTACs

Immunocore’s proprietary technology is focused on small protein molecules called ImmTACs (Immune mobilising monoclonal TCRs Against Cancer) that enable the immune system to recognise and kill cancerous. Immunocore's ImmTACs, a new class of drug with ultra-high affinity for intracellular cancer targets, are synthetic, soluble T cell receptors (TCRs) that recognise diseased cells containing disease specific targets. The ImmTACs enable circulating T-cells to selectively identify and kill diseased cells. The ImmTAC platform is unique in its high specificity and potency and broad applicability to a wide range of intracellular targets and disease indications. ImmTACs can access up to nine-fold more targets than typical antibody-based therapies, including monoclonal antibodies.

TCRs naturally recognise diseased cells and Immunocore’s world-leading competitive advantage is its ability to engineer high affinity TCRs and link them to an antibody fragment that activates a highly potent and specific T cell response to recognise and destroy cancer cells. The most advanced ImmTAC, IMCgp100, is currently in Phase I/IIa clinical trials for the treatment of late stage melanoma. Immunocore has a growing internal pipeline of ImmTACs addressing many different cancer types and has developed a broad database of intracellular cancer targets.

The TCR-based platform can address a significantly larger range of disease indications than currently respond to existing immuno-oncology agents and combine the characteristics of very high potency, encouraging safety and low cost of goods.

About Uveal Melanoma

Melanoma arises from pigment containing cells (melanocytes) present in the skin, eye and mucus membranes. Melanoma most frequently occurs in the skin, however ocular melanoma arises from pigmented cells in the eye. The primary cause of melanoma is thought to be radiation induced DNA damage from ultraviolet (UV) light exposure. Melanoma is the most deadly of skin cancers. Globally, in 2012, melanoma occurred in 232,000 people and resulted in 55,000 deaths. Uveal melanoma (UM) is a rare type of melanoma where the incidence has ranged from 5.3 to 10.9 cases per million (Singh 2003). Despite its rare incidence rate (representing approximately 3% of melanoma cases, approximately 4000 cases globally per year), UM is the most frequent primary intraocular malignancy of the adult eye in 85% of cases (Patel 2011, Maio 2013). Advanced uveal melanoma currently has no effective treatment options.

Contact information

Immunocore
Eliot Forster, Chief Executive Officer
T: +44 (0)1235 438600
E: info@immunocore.com
or
Consilium Strategic Communications
Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Laura Thornton
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

NMI Agrees to Acquire Creditcall to Expand EMV and Omnichannel Capabilities20.2.2018 13:04Pressemelding

NMI, a leading provider of payments enablement technology for independent sales organizations (ISOs), independent software vendors (ISVs), value-added resellers (VARs) and payment facilitators, today announced it has signed a definitive agreement to acquire Creditcall, an omnichannel payment gateway and EMV solutions provider. With offices in Bristol, England, and New York, and customers throughout many regions of the world, Creditcall will give NMI a global presence and access to new markets. This acquisition will continue to differentiate NMI from traditional payment gateway providers by further expanding its omnichannel and EMV capabilities, creating a one-of-a-kind payment gateway platform supporting all channels of commerce including retail, e-commerce, mobile and unattended. “The payment technology requirements of today’s merchants are more complex than ever—they need to accept and process payments in all sales channels and environments,” said Roy Banks, chief executive officer o

Philip Morris International and Scuderia Ferrari Partner Together to Advance the Vision of a World Free of Tobacco Smoke20.2.2018 13:00Pressemelding

Philip Morris International Inc. (NYSE/Euronext Paris: PMI) and Scuderia Ferrari have extended their partnership until 2021. Their successful collaboration spans more than 40 years. As of today, the partnership will be exclusively focused on advancing the cause of a smoke-free world – a world in which all people who would otherwise continue smoking switch from the most harmful form of nicotine consumption – cigarettes – to scientifically substantiated less harmful alternatives that are smoke-free. “We want to give the world’s 1.1 billion men and women who smoke the opportunity to make better and informed choices. We are committed to use all available resources, including our motorsports related activities, to accelerate momentum around this revolutionary change for the benefit of people who smoke, public health and society at large. We deeply appreciate Scuderia Ferrari’s support in this cause,” said PMI’s Chief Executive Officer, André Calantzopoulos. Creating global awareness of the

Legal & General Announces New Partnership with Technology Partner Slice Labs to Roll Out ‘On-Demand’ Homeshare Insurance20.2.2018 13:00Pressemelding

Legal & General, the FTSE 100 financial services group and leading home insurance provider, has today announced a new technology partnership with Slice Labs Inc with the aim to offer a new on-demand homeshare insurance proposition for customers. The last few years has seen an increase in the popularity of on-demand insurance which allows customers to use a mobile app to purchase insurance to protect their personal belongings, car, or home when ‘at risk’. On-demand insurance offers customers flexibility of cover that is easy and convenient to buy and paying only for what they need when they need it. The partnership with Slice Labs Inc is another step in Legal & General’s commitment to invest in new technology and intend to use Slice Labs Insurance Cloud Services™ (ICS) platform to roll out on-demand homeshare insurance and other products to their customers. Founded in October 2015 Slice Labs provides tailored insurance offerings for home sharing costs. The two companies are, working tog

Wipro Positioned in ‘Winner’s Circle’ of HfS Blueprint Report on Enterprise Blockchain Services 201720.2.2018 12:20Pressemelding

Wipro Limited (NYSE:WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been positioned in the ‘Winner's Circle’ of Enterprise Blockchain service providers by HfS Research in the market study ‘HfS Blueprint Report on Enterprise Blockchain Services 2017’. This report was authored by Saurabh Gupta, Chief Strategy Officer, HfS Research. In the Enterprise Blockchain Services 2017 Report, HfS evaluated the blockchain capabilities of 21 service providers across the value chain of Strategic Advisory, Prototype Development, Production build and System Integration. The 'Winner's Circle' of the HfS Blueprint represents service providers who excel at both execution and innovation dimensions. The report states that Wipro is a leading blockchain services provider with scale, robust partnership ecosystem, in-house tools and live client engagements. Phil Fersht, CEO, HfS Research said, “The blockchain mo

Jetcraft Opens First London Office20.2.2018 10:55Pressemelding

Jetcraft, the global leader in business aircraft sales and acquisitions, announces the opening of its first London office through its new UK company, Jetcraft Global (UK) Limited. The new London base cements Jetcraft’s commitment to the European region and demonstrates its confidence in the UK as a continuing hub of business opportunity. Chad Anderson, President at Jetcraft, says: “The opening of our London office comes as Jetcraft celebrates another record year -- with 93 transactions completed in 2017 – and rounds off a remarkable decade of more than 550 transactions exceeding $10bn in value. Our new London location creates even more ways for us to serve our clients and we are excited about the opportunities it presents.” Jetcraft’s new office comes at a time of significant growth in resources for the company, with the appointment of four senior sales posts from within the team, including Sean O’Leary, who will take on the role of Sales Director based in the new London office. Additi

Inmarsat Selects Sigma Systems for Large-Scale BSS Transformation20.2.2018 10:00Pressemelding

Sigma Systems, the global leader in catalog-driven software, is pleased to announce a multi-year contract with Inmarsat, the leading provider of global mobile satellite communications services. With the digital revolution moving forward at great speed, Inmarsat recognized that a catalog-driven, agile approach to B/OSS was key to enabling more effective connections with their customers and partners through the products and services they sell. To this end, Inmarsat awarded Sigma a multi-year contract for its Catalog, CPQ (Configure Price Quote) and Order Management products to support Inmarsat’s next-generation satellite services across all customer verticals. Kirk Wilkenson, VP OneIT Programme at Inmarsat, commented: “Inmarsat is focused on driving customer value and making it simpler for customers and partners to work with us. We are launching a new B/OSS platform, utilizing a service-oriented component architecture, as part of a broader service delivery transformation to support our c